Your Cart


Nature Communications just published a clinical study, including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection. Congratulations to this clinical research team. To date, the Apostle Minimax cfDNA technology has been used in 2 articles published in Nature Medicine, 1 in Nature Communications, 1 in Science Translational Medicine, 1 in PNAS, and over 50 scientific articles in different journals.